Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BDS-I
- Development stage
- Preclinical
- Modality
- Peptides
01
Overview
BDS-I (Blood Depressing Substance I) is a 43-amino acid peptide toxin originally isolated from the sea anemone *Actinia equina*. It is a potent and selective blocker of the voltage-gated potassium channel Kv3.4 (encoded by the KCNC4 gene). In oncological research, particularly concerning cervical cancer, BDS-I is used to investigate the role of Kv3.4 in cellular proliferation and metabolic activity. Research indicates that BDS-I treatment can selectively reduce the metabolic activity of HPV-transfected keratinocytes, suggesting that Kv3.4 is a viable therapeutic target and biomarker for early HPV-mediated cervical carcinogenesis. While primarily known for its affinity for Kv3.x channels, BDS-I has also demonstrated inhibitory effects on certain voltage-gated sodium channels, such as Nav1.7, at higher concentrations.
- Other names
- Blood depressing substance IBDS-I toxinActinia equina toxin BDS-I
02
Targets
KCNC1 (Kv3.1)KCNC4 (Potassium voltage-gated channel subfamily C member 4)SCN8A (NaV1.6)SCN3A (Sodium channel protein type 3 subunit alpha)SCN9A (Sodium channel protein type 9 subunit alpha)KCNC2 (Potassium voltage-gated channel subfamily C member 2)
Beyond the preview
Go deeper on BDS-I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BDS-I.